PMID- 36812900
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230626
IS  - 1421-9921 (Electronic)
IS  - 0014-312X (Linking)
VI  - 64
IP  - 2
DP  - 2023
TI  - Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without 
      Lenvatinib for Unresectable Hepatocellular Carcinoma.
PG  - 268-277
LID - 10.1159/000529475 [doi]
AB  - INTRODUCTION: For patients with advanced hepatocellular carcinoma (HCC), hepatic 
      artery infusion chemotherapy (HAIC) is a common and mature treatment, but the 
      safety and efficacy of HAIC combined with lenvatinib for advanced HCC patient 
      treatment remains unclear. Therefore, this study compared the safety and efficacy 
      of HAIC with or without lenvatinib in unresectable HCC patients. METHODS: We 
      retrospectively analyzed 13 unresectable advanced HCC patients who received HAIC 
      monotherapy or combination therapy of HAIC and lenvatinib. Overall survival (OS), 
      disease control rate (DCR), objective response rate (ORR), progression-free 
      survival (PFS), incidence of adverse events (AEs), and changes in liver function 
      were compared between the two groups. We applied a Cox regression analysis to 
      evaluate the independent risk factors affecting survival outcomes. RESULTS: The 
      ORR in the HAIC+lenvatinib group was markedly increased compared to the HAIC 
      group (p < 0.05), while the DCR in the HAIC group was higher (p > 0.05). No 
      notable difference was found between the two groups in median OS and PFS (p > 
      0.05). Compared to the HAIC+lenvatinib group, more patients had improved liver 
      function in the HAIC group after treatment, but the difference was not dramatical 
      (p > 0.05). The AEs incidence was 100.00% in both groups, which was relieved 
      with corresponding treatment. Besides, Cox regression analysis did not identify 
      independent risk factors related to OS and PFS. CONCLUSION: Combination therapy 
      of HAIC and lenvatinib notably performed better than the HAIC monotherapy in 
      patients with unresectable HCC in terms of ORR and was well tolerated, which 
      deserves further investigation with large-scale clinical trials.
CI  - (c) 2023 S. Karger AG, Basel.
FAU - Yuan, Wei
AU  - Yuan W
AD  - Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi 
      Medical University, Yangquan, China.
AD  - Department of Oncology, General Hospital of Yangquan Coal Industry Group, 
      Yangquan, China.
FAU - Yue, Wenchao
AU  - Yue W
AD  - Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi 
      Medical University, Yangquan, China.
AD  - Department of Oncology, General Hospital of Yangquan Coal Industry Group, 
      Yangquan, China.
FAU - Wen, Huabing
AU  - Wen H
AD  - Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi 
      Medical University, Yangquan, China.
AD  - Department of Oncology, General Hospital of Yangquan Coal Industry Group, 
      Yangquan, China.
FAU - Wang, Xueqin
AU  - Wang X
AD  - Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi 
      Medical University, Yangquan, China.
AD  - Department of Oncology, General Hospital of Yangquan Coal Industry Group, 
      Yangquan, China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Oncology and Interventional Radiology, Yang Quan Hospital of Shanxi 
      Medical University, Yangquan, China.
AD  - Department of Oncology, General Hospital of Yangquan Coal Industry Group, 
      Yangquan, China.
LA  - eng
PT  - Journal Article
DEP - 20230222
PL  - Switzerland
TA  - Eur Surg Res
JT  - European surgical research. Europaische chirurgische Forschung. Recherches 
      chirurgicales europeennes
JID - 0174752
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - Hepatic Artery/pathology
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Efficacy
OT  - Hepatic artery infusion chemotherapy
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
EDAT- 2023/02/23 06:00
MHDA- 2023/06/26 06:41
CRDT- 2023/02/22 18:23
PHST- 2022/09/20 00:00 [received]
PHST- 2023/01/30 00:00 [accepted]
PHST- 2023/06/26 06:41 [medline]
PHST- 2023/02/23 06:00 [pubmed]
PHST- 2023/02/22 18:23 [entrez]
AID - 000529475 [pii]
AID - 10.1159/000529475 [doi]
PST - ppublish
SO  - Eur Surg Res. 2023;64(2):268-277. doi: 10.1159/000529475. Epub 2023 Feb 22.